- Home
- AHH vs PRAX Comparison
AHH vs PRAX Comparison
Compare AHH & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AHH
- PRAX
- Stock Information
- Founded
- AHH 1979
- PRAX 2015
- Country
- AHH United States
- PRAX United States
- Employees
- AHH N/A
- PRAX N/A
- Industry
- AHH Real Estate
- PRAX Biotechnology: Pharmaceutical Preparations
- Sector
- AHH Finance
- PRAX Health Care
- Exchange
- AHH Nasdaq
- PRAX Nasdaq
- Market Cap
- AHH 557.9M
- PRAX 599.7M
- IPO Year
- AHH 2013
- PRAX 2020
- Fundamental
- Price
- AHH $6.92
- PRAX $43.81
- Analyst Decision
- AHH Buy
- PRAX Strong Buy
- Analyst Count
- AHH 3
- PRAX 11
- Target Price
- AHH $9.83
- PRAX $114.73
- AVG Volume (30 Days)
- AHH 797.7K
- PRAX 296.2K
- Earning Date
- AHH 08-06-2025
- PRAX 08-12-2025
- Dividend Yield
- AHH 10.96%
- PRAX N/A
- EPS Growth
- AHH 9.49
- PRAX N/A
- EPS
- AHH 0.10
- PRAX N/A
- Revenue
- AHH $627,963,000.00
- PRAX $8,122,000.00
- Revenue This Year
- AHH N/A
- PRAX N/A
- Revenue Next Year
- AHH $2.11
- PRAX N/A
- P/E Ratio
- AHH $71.41
- PRAX N/A
- Revenue Growth
- AHH N/A
- PRAX 270.02
- 52 Week Low
- AHH $6.10
- PRAX $26.70
- 52 Week High
- AHH $12.46
- PRAX $91.83
- Technical
- Relative Strength Index (RSI)
- AHH 44.69
- PRAX 61.35
- Support Level
- AHH $6.83
- PRAX $43.44
- Resistance Level
- AHH $7.17
- PRAX $46.93
- Average True Range (ATR)
- AHH 0.14
- PRAX 2.58
- MACD
- AHH -0.01
- PRAX 0.35
- Stochastic Oscillator
- AHH 24.29
- PRAX 73.38
About AHH Armada Hoffler Properties Inc.
Armada Hoffler Properties Inc is a real estate company. It engages in developing, building, owning and managing the high-quality, institutional-grade office, retail, and multifamily properties in various markets throughout the Mid-Atlantic and Southeastern United States. It lease its properties under operating leases and recognize base rents. It also recognize revenue from tenant recoveries, through which tenants reimburses the company for expenses paid by them such as utilities, janitorial, repairs and maintenance. The company's operating segment includes office real estate, retail real estate, multifamily residential real estate, and general contracting, real estate financing and real estate services. It generates maximum revenue from the retail real estate segment.
About PRAX Praxis Precision Medicines Inc.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.